Aivlosin 42.5 mg/g Premix for Medicated Feeding Stuff for Pigs

国: イギリス

言語: 英語

ソース: VMD (Veterinary Medicines Directorate)

有効成分:

Tylvalosin

から入手可能:

Eco Animal Health Ltd

ATCコード:

QJ01FA92

INN（国際名）:

Tylvalosin

医薬品形態:

Premix for medicated feeding stuff

処方タイプ:

POM-V - Prescription Only Medicine – Veterinarian

治療群:

Pigs

治療領域:

Antimicrobial

認証ステータス:

Authorized

承認日:

2004-09-09

製品の特徴

Revised: September 2023
AN: 01857/2022
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Aivlosin 42.5 mg/g premix for medicated feeding stuff for pigs
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Tylvalosin (as tylvalosin tartrate) 42.5 mg/g
For the full list of excipients see section 6.1.
3. PHARMACEUTICAL FORM
Premix for medicated feeding stuff.
A beige granular powder.
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES
Pigs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment and metaphylaxis of swine enzootic pneumonia caused by
susceptible
strains of _Mycoplasma_ _hyopneumoniae_ in pigs. At the recommended
dose, lung
lesions and weight loss are reduced but infection with _Mycoplasma
hyopneumoniae_
is not eliminated.
Treatment of porcine proliferative enteropathy (ileitis) caused by
_Lawsonia _
_intracellularis_ in herds where there is a diagnosis based on
clinical history, post-
mortem findings and clinical pathology results.
Treatment and metaphylaxis of swine dysentery, caused by _Brachyspira
_
_hyodysenteriae _in herds where the disease has been diagnosed.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Acute cases and severely diseased pigs with reduced food or water
intake should be
treated with a suitable injectable product.
Revised: September 2023
AN: 01857/2022
Page 2 of 6
Generally, strains of _B. hyodysenteriae_ have higher minimal
inhibitory concentration
(MIC) values in cases of resistance against other macrolides, such as
tylosin. The
clinical relevance of this reduced susceptibility is not fully
explored. Cross-resistance
between tylvalosin and other macrolides cannot be excluded.
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Good management and hygiene practices should be followed to reduce the
risk of re-
infection.
It is sound clinical practice to base treatment on susceptibility
testing of the bacteria
isolated from the animal. If this is not possible, therapy should be
based on